Med. Pro Praxi 2009; 6(5): 260-264

Problems of benign prostatatic hyperplasia at the general practice

MUDr. Ondřej Kaplan1,2, MUDr. Kamil Belej, Ph.D., FEBU2
1 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
2 Urologické oddělení Ústřední vojenská nemocnice, Praha

The care for patients with benign prostatatic hyperplasia (BPH) is in our circumstances in the hands of the urologist. Despite that, the essential

knowledge of the etiopatogenesis, diagnostics and treatment can be useful for the general practitioner’s, it can facilitate their care

for these patients and improve their collaboration with the specialist. The article summarises the contemporary view on that problems

and provides with practical information about the strategy of the care for patients with this most common male urological disease.

Keywords: prostate, benign prostatatic hyperplasia, PSA, sonography.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaplan O, Belej K. Problems of benign prostatatic hyperplasia at the general practice. Med. praxi. 2009;6(5):260-264.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McNeal JE. The zonal anatomy of the prostate. Prostate 1981; 2(1): 35-49. Go to original source... Go to PubMed...
    2. Oishi K, Boyle P, Barry JM, et al. Epidemiology and natural history of benign prostatic hyperplasia. In: Denis L, Griffiths K, Khoury S, et al. (eds). Fourth International Consultation on BPH, Paris, July 1997. Plymouth: Health Publications, 1998: 25-59.
    3. Berry SJ, Coffey DS, Walsh PC, Ewirig LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479. Go to original source... Go to PubMed...
    4. Berges RR, Pientka L. Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 1999; 36(Suppl 3): 21-27. Go to original source... Go to PubMed...
    5. Belej K. Prostatitický syndrom - asymptomatická prostatitida. Urolog. pro Praxi 2007; 8(6): 281-284.
    6. Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000; 37: 528-536. Go to original source... Go to PubMed...
    7. Roehrborn CG, Malice MP, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-216. Go to original source... Go to PubMed...
    8. Roehrborn CG, McConnell JD, Saltzman B, et al. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002; 42: 1-6. Go to original source... Go to PubMed...
    9. Abrams P. Objective evaluation of bladder outlet obstruction-review. Br J Urol 1995; 76(suppl 1): 11-15. Go to PubMed...
    10. Belej K. Transrektální sonografie v diagnostice onemocnění prostaty. Urolog. pro Praxi 2009; 10(1): 363-366.
    11. Andersen JT, Ekman P, Wolf H. Can finasteride reverse the progress of benign prostate hyperplasia. A two year placebocontrolled study. The Scandinavian BPH Study Group. Urology 1995; 46: 631-637. Go to original source... Go to PubMed...
    12. McConell JD, for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of BPH: results from MTOPS trial (Abstrakt 1042). J Urol 2002; 167(4, Suppl): 265. Go to PubMed...
    13. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003; 24: 224-243. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.